Satellos's SAT-3247 follow-up study doses first patient

Executive Summary

• Satellos Bioscience Inc. has announced the dosing of the first patient in LT-001, an open-label, long-term follow-up study of its drug candidate SAT-3247 in adult males with Duchenne muscular dystrophy (DMD).
• The study aims to evaluate longer-term safety, changes in muscle composition via MRI, and functional outcomes in participants who previously completed Part D of the phase 1b 28-day study.
• Satellos plans to expand the protocol to include up to 10 new participants in Australia and intends to open the study in the United States, pending regulatory and clinical site approvals.

Key Details

• Study Name: LT-001 (Open-label, long-term follow-up study).
• Drug Candidate: SAT-3247, a novel oral small molecule therapeutic designed to repair and regenerate muscle lost in DMD.
• Target Population: Adult males with Duchenne muscular dystrophy (DMD) who previously completed Part D of the phase 1b 28-day study.
• Study Objectives: Evaluate longer-term safety, changes in muscle composition by MRI, and functional outcomes.
• Assessment Schedule: Patient assessments and reporting occur every three months during treatment.
• Current Status: The trial is underway at St. Vincent's Hospital in Melbourne, Australia.
• Key Investigator: Dr. Gayatri Jain, MD (clinical neurologist and neurophysiologist).
• Expansion Plans: The company is working to expand the protocol to include up to 10 new participants in Australia and plans to open the study in the United States (subject to regulatory and clinical site approvals).
• Mechanism of Action: SAT-3247 targets AAK1, a key protein identified by Satellos as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is being developed independent of dystrophin and regardless of exon mutation status.

Notable Quotes

• Frank Gleeson, Co-founder and CEO: "Dosing the first patient in LT-001 marks an important milestone as we work to unlock the long-term potential of SAT-3247 for people living with Duchenne... If we find the benefits observed in the initial phase 1b adult study are strengthened and maintained in our long-term follow up, we will be another step closer to the possibility of a therapy that can reverse the effects of Duchenne -- thereby making a real and lasting difference for patients and families living in this devastating disease."
• Dr. Gayatri Jain, Key Investigator: "Seeing the first patient enrolled in LT-001 is a hopeful moment for the Duchenne community... We look forward to evaluating long-term safety of SAT-3247, as well as how SAT-3247 may sustain functional improvements and positively affect muscle composition over time, providing valuable insights into its potential to improve patients' daily lives."